Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.

Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.

Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.

The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.

Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.

The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.

Judy E. Garber, MD, MPH, of the Dana Farber Cancer Institute is the recipient of the 2026 Basser Global Prize.

The European Commission approved T-DXd for patients with HER2+ breast cancer who have residual invasive disease after neoadjuvant treatment.